2020年11月25日 | 59:21
Catch up on the third and final webinar in our 2020 series on decisions in the United States and Europe impacting biologics and biosimilars.
Many of the top-selling drugs worldwide are biologics and several companies are seeking to produce biosimilars to compete in these lucrative markets. However, companies continue to face a great deal of uncertainty due to unresolved legal questions involving the governing statutes and patent rights.
Session 3 focuses on recent key developments in the United States and Europe, including: